Your browser doesn't support javascript.
loading
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.
Mair, Maximilian J; Mitterer, Manfred; Gattinger, Pia; Berger, Julia M; Trutschnig, Wolfgang; Bathke, Arne C; Gansterer, Margaretha; Berghoff, Anna S; Laengle, Severin; Gottmann, Lynn; Buratti, Thomas; Haslacher, Helmuth; Lamm, Wolfgang W; Raderer, Markus; Tobudic, Selma; Fuereder, Thorsten; Valenta, Rudolf; Fong, Dominic; Preusser, Matthias.
Afiliação
  • Mair MJ; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Mitterer M; Hemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
  • Gattinger P; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Berger JM; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Trutschnig W; Department of Artificial Intelligence and Human Interfaces and Intelligent Data Analytics Lab Salzburg, University of Salzburg, Salzburg, Austria.
  • Bathke AC; Department of Artificial Intelligence and Human Interfaces and Intelligent Data Analytics Lab Salzburg, University of Salzburg, Salzburg, Austria.
  • Gansterer M; Faculty of Management and Economics, University of Klagenfurt, Klagenfurt, Austria.
  • Berghoff AS; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Laengle S; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Gottmann L; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Buratti T; Hemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
  • Haslacher H; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Lamm WW; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Raderer M; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Tobudic S; Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Fuereder T; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Valenta R; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Fong D; Hemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
  • Preusser M; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: matthias.preusser@meduniwien.ac.at.
Cancer Cell ; 40(5): 444-446, 2022 05 09.
Article em En | MEDLINE | ID: mdl-35429443
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria